Vallelunga Annamaria, Iannitti Tommaso, Dati Giovanna, Capece Sabrina, Maugeri Marco, Tocci Ersilia, Picillo Marina, Volpe Giampiero, Cozzolino Autilia, Squillante Massimo, Cicarelli Giulio, Barone Paolo, Pellecchia Maria Teresa
Neuroscience Section, Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Salerno, Italy.
KWS BioTest, Marine View Office Park, Portishead, Somerset, BS20 7AW, UK.
Mol Biol Rep. 2019 Apr;46(2):1661-1666. doi: 10.1007/s11033-019-04614-z. Epub 2019 Feb 27.
Multiple system atrophy (MSA) is a neurodegenerative disease that belongs to the α synucleinopathies. Clinically, there is an overlap between MSA and Parkinson's disease (PD), especially at the early disease stage. However, these two pathologies differ in terms of disease progression. Currently, no biomarker exists to differentiate MSA from PD. MicroRNAs are non-coding RNAs implicated in gene expression regulation. MiRNAs modulate cellular activity and they control a range of physiological and pathological functions. miRNAs are found in biofluids, such as blood, serum, plasma, saliva, and cerebrospinal fluid. Many groups, including ours, found that circulating miRNAs are differently expressed in blood, plasma, serum and cerebrospinal fluid of PD and MSA patients. In the present study, our primary aim was to determine if serum mir-30-5p and mir-148b-5p can be used as biomarkers for early diagnosis of PD and/or MSA. Our secondary goal was to determine if serum levels of those miRNAs can be correlated with the patients' clinical profile. Using quantitative PCR (qPCR), we evaluated expression levels of miR-30c-5p and miR148b-5p in serum samples from PD (n = 56), MSA (n = 49), and healthy control (n = 50) subjects. We have found that miR-30c-5p is significantly upregulated in MSA if compared with PD and healthy control subjects. Moreover, serum miR-30c-5p levels correlate with disease duration in both MSA and PD. No significant difference was found in miR-148b-5p among MSA, PD and healthy control subjects. Our results suggest a possible role of serum miR-30-5p as a biomarker for diagnosis and progression of MSA.
多系统萎缩（MSA）是一种属于α-突触核蛋白病的神经退行性疾病。临床上，MSA与帕金森病（PD）存在重叠，尤其是在疾病早期阶段。然而，这两种病理状况在疾病进展方面有所不同。目前，尚无生物标志物可用于区分MSA和PD。微小RNA是参与基因表达调控的非编码RNA。微小RNA调节细胞活性并控制一系列生理和病理功能。微小RNA存在于生物体液中，如血液、血清、血浆、唾液和脑脊液。包括我们在内的许多研究小组发现，PD和MSA患者的血液、血浆、血清和脑脊液中循环微小RNA的表达存在差异。在本研究中，我们的主要目的是确定血清mir-30-5p和mir-148b-5p是否可作为PD和/或MSA早期诊断的生物标志物。我们的次要目标是确定这些微小RNA的血清水平是否与患者的临床特征相关。使用定量PCR（qPCR），我们评估了PD（n = 56）、MSA（n = 49）和健康对照（n = 50）受试者血清样本中miR-30c-5p和miR148b-5p的表达水平。我们发现，与PD和健康对照受试者相比，MSA中miR-30c-5p显著上调。此外，血清miR-30c-5p水平与MSA和PD的疾病持续时间相关。MSA、PD和健康对照受试者之间的miR-148b-5p未发现显著差异。我们的结果表明血清miR-30-5p可能作为MSA诊断和病情进展的生物标志物。
